5 days ago
Stifel Nicolaus Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
In a report released on June 2, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), with a price target of $48.00. The company's shares closed yesterday at $11.01.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Willey covers the Healthcare sector, focusing on stocks such as Bicara Therapeutics Inc., Exelixis, and Abeona Therapeutics. According to TipRanks, Willey has an average return of 0.5% and a 37.45% success rate on recommended stocks.
In addition to Stifel Nicolaus, Bicara Therapeutics Inc. also received a Buy from H.C. Wainwright's Robert Burns in a report issued yesterday. However, on May 23, Wells Fargo upgraded Bicara Therapeutics Inc. (NASDAQ: BCAX) to a Hold.
